JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2017, Vol. 55 ›› Issue (3): 100-106.doi: 10.6040/j.issn.1671-7554.0.2016.1471

Previous Articles     Next Articles

The role of CIP2A in the transformation of breast ductal epithelium and prognosis of invasive breast cancer

LIN Jiaxiang1, GUO Zijia2, SU Peng3, WANG Xiao1, GUO Yaxin4, WU Xiaojuan1, XIANG Lei1, ZHOU Zhiqiang1, WANG Yan1, CUI Xiujie1, PAN Aifeng1, GUO Chenghao1   

  1. 1. Department of Pathology, School of Medicine, Shandong University, Jinan 250012, Shandong, China;
    2. Department of Gynecology of Chinese Medicine, First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250012, Shandong, China;
    3. Department of Pathology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
    4. School of Public Health, Shandong University, Jinan 250012, Shandong, China
  • Received:2016-11-09 Online:2017-03-10 Published:2017-03-10

Abstract: Objective To explore the role of cancerous inhibitor of protein phosphatase 2A(CIP2A)in the malignant transformation of breast ductal epithelium and its association with the prognosis of breast ductal cancer. Methods Immunohistochemistry staining was used to detect CIP2A protein in 322 paraffin-embedded breast samples including normal breast duct, usual ductal hyperplasia(UDH), atypical ductal hyperplasia(ADH), ductal carcinoma in situ(DCIS)and invasive ductal carcinoma(IDC). Chi-square test was used to assess the difference of CIP2A expressions, and the correlation between CIP2A expression and the clinicopathologic characteristics. Kaplan-Meier method and Cox proportional hazard regression model were adopted to analyze the survival rate of patients. Results The expression rate 山 东 大 学 学 报 (医 学 版)55卷3期 -林家香,等.致癌蛋白CIP2A在乳腺导管上皮恶变中的作用及预测浸润性导管癌患者预后的能力 \=-of CIP2A in of normal tissue, UDH, ADH, DCIS and IDC was 6.66%, 5.13%, 6.66%, 32.35% and 32.45%, respectively. There was significant difference between UDH and DCIS groups, and UDH and IDC groups(P=0.004 3, P=0.004 0). Furthermore, CIP2A expression was closely associated with high histological grade and Ki67 index in DCIS samples(both P<0.05). In IDC patients, CIP2A expression was significantly correlated with CerbB2(Her-2)positive expression, high Ki67 index, high TNM stage and lymph node metastasis(all P<0.05). Patients with positive CIP2A expression exhibited significantly shortened 5-year disease-free and overall survival rate. CIP2A could be an independent prognostic indicator for IDC. Conclusion CIP2A plays a key role in the transition from proliferative lesions to ductal carcinoma. It holds the potential to monitor the malignant transformation of breast duct epithelium, and to guide the prognosis and personal treatment of patients with breast cancer.

Key words: Usual ductal hyperplasia, Atypical ductal hyperplasia, Cancerous inhibitor of protein phosphatase 2A, Ductal carcinoma in situ, Prognosis, Invasive ductal cancer

CLC Number: 

  • R737.9
[1] Huang Z, Wen W, Zheng Y, et al. Breast cancer incidence and mortality: trends over 40 years among women in Shanghai, China[J]. Ann Oncol, 2016, 27(6): 1129-1134.
[2] 庄婷, 薛梅, 房爱菊, 等. 黏蛋白(MUC1、MUC2、MUC5AC和MUC6)在乳腺浸润性导管癌中的表达及意义[J]. 山东大学学报(医学版), 2012, 50(5): 107-111. ZHUANG Ting, XUE Mei, FANG Aiju, et al. Expression of mucins(MUC1, MUC2, MUC5AC and MUC6)and their significance in invasive ductal breast carcinoma[J]. Journal of Shandong University(Health Sciences), 2012, 50(5): 107-111.
[3] 高永生, 王春健, 蔡淑萍, 等. Netrin-1在乳腺浸润性导管癌中的表达及与转移的相关性[J]. 山东大学学报(医学版), 2015, 53(7): 39-42. GAO Yongsheng, WANG Chunjian, CAI Shuping, et al. Expression of netrin-1 in invasive ductal breast cancer and its relationship with tumor metastasis [J]. Journal of Shandong University(Health Sciences), 2015, 53(7): 39-42.
[4] Sgroi DC. Preinvasive breast cancer [J]. Annu Rev Pathol, 2010,(5): 193-221.
[5] Tavassoli FA, Devilee P. Pathology and genetics: tumours of the breast and female genital organs [M]. Lyon, France, IARC Press, 2003.
[6] Junttila MR, Puustinen P, Niemel M, et al. CIP2A inhibits PP2A in human malignancies [J]. Cell, 2007, 130(1): 51-62.
[7] De P, Carlson J, Leyland-Jones B, et al. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A(CIP2A): an oncoprotein with many hands [J]. Oncotarget, 2014, 5(13): 4581-4602.
[8] Ventelä S, Sittig E, Mannermaa L, et al. CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance [J]. Oncotarget, 2015, 6(1): 144-158.
[9] Wiegering A, Pfann C, Uthe FW, et al. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression [J]. PLoS One, 2013, 8(10): 75292.
[10] Dong QZ, Wang Y, Dong XJ, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis [J]. Ann Surg Oncol, 2011, 18(3): 857-865.
[11] Liu J, Wang X, Zhou G, et al. Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein [J]. Gynecol Oncol, 2011, 122(2): 430-436.
[12] Yu HC, Chen HJ, Chang YL, et al. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma [J]. Biochem Pharmacol, 2013, 85(3): 356-366.
[13] Zhang W, Chen H, Chen Y, et al. Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1 [J]. Oncotarget, 2015, 6(7): 5253-5262.
[14] Laine A, Sihto H, Come C, et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1 [J]. Cancer Discov, 2013, 3(2): 182-197.
[15] Puustinen P, Jäättelä M. KIAA1524/CIP2A promotes cancer growth by coordinating the activities of MTORC1 and MYC [J]. Autophagy, 2014, 10(7): 1352-1354.
[16] Böckelman C, Hagström J, Mäkinen LK, et al. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer [J]. Br J Cancer, 2011, 104(12): 1890-1895.
[17] Chen JS, Wu BB, Bao HL, et al. Relationship between CIP2A expression, and prognosis and MDR-related proteins in patients with advanced gastric cancer [J]. Int J Clin Exp Pathol, 2015, 8(11): 15007-15012.
[18] Li W, Ge Z, Liu C, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells [J]. Clin Cancer Res, 2008, 14(12): 3722-3728.
[19] Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update [J]. Clin Oncol, 2013, 31(31): 3997-4013.
[20] Mommers EC, Leonhart AM, Falix F, et al. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade [J]. J Pathol, 2001, 194(3): 327-333.
[21] Niemelä M, Kauko O, Sihto H, et al. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes [J]. Oncogene, 2012, 31(39): 4266-4278.
[22] Côme C, Laine A, Chanrion M, et al. CIP2A is associated with human breast cancer aggressivity [J]. Clin Cancer Res, 2009, 15(16): 5092-5100.
[23] Kim JS, Kim EJ, Oh JS, et al. CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1 [J]. Cancer Res, 2013, 73(22): 6667-6678.
[24] Pallai R, Bhaskar A, Barnett-Bernodat N, et al. Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells [J]. Tumour Biol, 2015, 36(8): 6383-6390.
[25] Böckelman C, Lassus H, Hemmes A, et al. Prognostic role of CIP2A expression in serous ovarian cancer [J]. Br J Cancer, 2011, 105(7): 989-995.
[26] Flørenes VA, Emilsen E, Dong HP, et al. Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma [J]. Cancer Med, 2015, 4(6): 903-913.
[1] LI Yinglin, SONG Daoqing, XU Zhonghua. Identification of FKBP11 expression in clear cell renal cell carcinoma using bioinformatics analysis [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 45-51.
[2] SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 47-52.
[3] LI Xingkai, LIU Zhanye, JIANG Yunfeng, LI Jun. Clinicopathological factors and prognosis between primary central and peripheral lung squamous cell carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 73-78.
[4] ZONG Shuai, XIAO Dongjie, LIU Hua, JIA Yanfei, MA Xiaoli, LI Huanjie, LI Ping, ZHENG Yan, WANG Yunshan. Expression of CSN5 and its correlation with the prognosis of gastric carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 12-16.
[5] SUN Qijing, CHEN Fangfang, LI Chunxiao, ZHANG Caiqing. Clinical value of PNI and HGB in evaluating the prognosis of the middle to late stage non-small cell lung cancer patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 55-59.
[6] ZHOU Lanlan, PAN Xueyi, GUO Yu. Clinical characteristics and prognosis of 48 patients with mixed phenotype acute leukemia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 79-83.
[7] ZHANG Xiying, ZHAI Chunyan, LI Jingsong, HAN Bo. Expression of EZH2 in Chinese Ewing sarcoma patients and its relationship with clinicopathological parameters and prognosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 84-91.
[8] LIU Huiling, WANG Xingwen, FENG Shaobin, FENG Hong, HAN Junqing. Association between high expression of scavenger receptor class B type I and the prognosis of colon cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 84-89.
[9] LI Xiaoning, CUI Lianqun. Treatment timing of non-infarct-related artery in patients with multi-vessel disease and acute myocardial infarction [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 50-54.
[10] WANG Wen, LIU Yao, LONG Fei, MA Weixia, SU Lili. Correlation between lymphocyte-to-monocyte ratio in peripheral blood and prognosis of malignant pleural mesothelioma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 72-77.
[11] LIU Tong, ZHANG Xin, WANG Chuanxin. Significance of IRX5 mRNA in the diagnosis and prognosis of colorectal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 69-74.
[12] MA Lin, ZHANG Dong, TANG Lei, YE Siyuan, YAN Chuanzhu, CAO Lili. Prognostic hematological biomarkers of amyotrophic lateral sclerosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(4): 46-50.
[13] XU Zhihong, WU Xiaohua, YAO Tiezhu, WANG Xiaoxiang, DUAN Xiaoyang, SHI Jian. Relationship between mir-99a expression and prognosis of epithelial ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 77-80.
[14] QU Lixin, SHI Xinghua, DU Yifeng. Relationship between circulating platelets microparticles and endothelial microparticls and prognosis in patients with acute ischemic stroke [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(12): 32-36.
[15] LIU Xiao, LIU Zhiguang, FAN Zhisong, WANG Yuan, YANG Xingxiao, KONG Jieyu, CHEN Junzhuo, LIU Junxia. Prognostic analysis of patients with severe sepsis and septic shock [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(10): 80-84.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd